Current challenges in the management of epilepsy

Area of Science:

• Neurology
• Pharmacology
• Epilepsy Research

Background:

• Epilepsy classification, diagnosis, and treatment have evolved significantly.
• The selection of antiepileptic drugs (AEDs) is complex due to numerous new options.
• Initial seizure type (partial vs. generalized) is critical for guiding treatment.

Purpose of the Study:

• To review recent advances in epilepsy treatment and antiepileptic drug selection.
• To discuss the complexities and considerations in choosing appropriate AEDs.
• To highlight the ongoing need for more effective epilepsy therapies.

Main Methods:

• Review of recent conceptual reconsiderations and therapeutic advances in epilepsy.
• Analysis of US Food and Drug Administration approvals for new AEDs and devices since 1993.
• Examination of evidence from randomized controlled trials and secondary analyses of clinical trial data.

Main Results:

• Twelve new AEDs and one device approved since 1993 have increased treatment complexity.
• Predicting patient response to AEDs based on clinical features or lab results is currently impossible.
• Newer AEDs generally offer better pharmacokinetic profiles and tolerability, but adverse effects vary widely.
• Few head-to-head trials exist, making first-choice or first add-on drug selection challenging.
• A secondary analysis suggests combining lacosamide with non-sodium channel AEDs may improve outcomes.
• Approximately one-third of epilepsy patients remain inadequately controlled with current AEDs.

Conclusions:

• Individualized AED selection, considering comorbidities and tolerability, is essential.
• Despite advances, significant unmet needs exist for effective epilepsy treatments.
• Epilepsy surgery is an underutilized, highly effective option for medication-resistant cases.